Ascendis Pharma A/S Q1 Earnings Call Highlights

3 days ago 3

MarketBeat

Thu, May 7, 2026 astatine 9:14 AM CDT 8 min read

Ascendis Pharma A/S logo

Key Points

FDA approval of Ascendis's 3rd TransCon product, YUVIWEL, was secured and the therapy launched successful aboriginal April, already prescribed for much than 60 children crossed 35+ providers; absorption plans to brace YUVIWEL with once‑weekly SKYTROFA to fortify enactment successful maturation disorders.
Q1 2026 results showed beardown commercialized show with full gross of EUR 247 million (YORVIPATH EUR 197M, SKYTROFA EUR 44M), operating nett of EUR 25M (non‑IFRS EUR 55M), a currency equilibrium of EUR 573M, and notable firm actions including a Nasdaq nonstop listing, afloat redemption of convertible notes and a $187.5M merchantability of a precedence reappraisal voucher.
Pipeline highlights see compelling Phase II achondroplasia operation information (TransCon CNP + TransCon hGH) with precocious retention, portion the institution has exited interior oncology improvement to ore connected its uncommon endocrine portfolio and prosecute alternate ways to monetize oncology assets.
Interested successful Ascendis Pharma A/S? Here are 5 stocks we similar better.

Can BioMarin Stock Live Up to Wall Street’s High Expectations?

Ascendis Pharma A/S (NASDAQ:ASND) reported first-quarter 2026 results highlighted by the U.S. FDA support of its 3rd TransCon product, YUVIWEL, and continued maturation crossed its uncommon endocrine portfolio. President and CEO Jan Mikkelsen said the 4th marked “FDA support of our 3rd TransCon product, UbeWell,” adding that the company’s “revenues are increasing rapidly” and that Ascendis is “profitable” with “a pipeline of high-value merchandise opportunities to enactment semipermanent growth.”

Commercial portfolio: YORVIPATH, SKYTROFA, and aboriginal YUVIWEL motorboat

Mikkelsen emphasized the company’s presumption successful uncommon endocrine disease, pointing to 3 FDA-approved TransCon products crossed 4 uncommon endocrine indications and much than 20 ongoing oregon planned objective trials aimed astatine statement and marketplace expansion.

→ The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It Launches

3 Oversold Stocks with Big RSI Rebound Potential

In hypoparathyroidism, absorption reiterated semipermanent expectations for YORVIPATH, citing an estimated 70,000 to 90,000 chronic hypoparathyroidism patients successful the U.S. and “5 to 10 times that fig extracurricular the U.S.” Mikkelsen said Ascendis continues to prosecute enlargement opportunities including doses up to 60 micrograms successful the U.S., enlargement to patients aged 12 to 18 globally, and improvement of a once-weekly TransCon PTH enactment for patients unchangeable connected YORVIPATH.

In maturation disorders, Mikkelsen said Ascendis believes it is “uniquely positioned to fortify its leadership” by pairing once-weekly YUVIWEL with once-weekly maturation hormone SKYTROFA. He said YUVIWEL became commercially disposable successful aboriginal April and, since then, had been prescribed for “more than 60 children by much than 35 unsocial healthcare providers,” with immoderate children “approved for reimbursement arsenic accelerated arsenic a fewer days.”

Read Entire Article